Samantha Semenkow
Stock Analyst at Citigroup
(3.29)
# 2,821
Out of 5,182 analysts
79
Total ratings
43.28%
Success rate
5.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $123 → $151 | $86.74 | +74.09% | 3 | Apr 21, 2026 | |
| BHVN Biohaven | Maintains: Buy | $14 → $17 | $9.59 | +77.27% | 3 | Apr 2, 2026 | |
| BEAM Beam Therapeutics | Maintains: Buy | $64 → $68 | $29.17 | +133.16% | 4 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $131 → $142 | $85.20 | +66.67% | 3 | Mar 20, 2026 | |
| BIOA BioAge Labs | Maintains: Buy | $15 → $52 | $18.06 | +187.93% | 6 | Mar 10, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $38 → $46 | $24.43 | +88.29% | 2 | Mar 5, 2026 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $33 → $35 | $29.27 | +19.58% | 4 | Mar 3, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $4.44 | +215.32% | 7 | Feb 25, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $33 | $13.25 | +149.06% | 1 | Feb 17, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $35 | $27.85 | +25.67% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,124 → $1,091 | $783.74 | +39.20% | 8 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $15 | $14.49 | +0.07% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $71.90 | -10.99% | 1 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $30 | $6.94 | +332.28% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $100 | $45.33 | +120.60% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4.25 | $3.67 | +15.80% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $16.85 | -70.33% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $2.91 | +243.64% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.25 | +77.78% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.76 | +219.15% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $3.26 | +360.12% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $31.54 | +153.65% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.89 | +419.03% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $28.62 | +74.70% | 3 | Sep 27, 2023 |
Nektar Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $123 → $151
Current: $86.74
Upside: +74.09%
Biohaven
Apr 2, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $9.59
Upside: +77.27%
Beam Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $64 → $68
Current: $29.17
Upside: +133.16%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $131 → $142
Current: $85.20
Upside: +66.67%
BioAge Labs
Mar 10, 2026
Maintains: Buy
Price Target: $15 → $52
Current: $18.06
Upside: +187.93%
Agios Pharmaceuticals
Mar 5, 2026
Maintains: Buy
Price Target: $38 → $46
Current: $24.43
Upside: +88.29%
Catalyst Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $29.27
Upside: +19.58%
Larimar Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $4.44
Upside: +215.32%
Cullinan Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $33
Current: $13.25
Upside: +149.06%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $35
Current: $27.85
Upside: +25.67%
Jan 8, 2026
Maintains: Buy
Price Target: $1,124 → $1,091
Current: $783.74
Upside: +39.20%
Dec 22, 2025
Downgrades: Neutral
Price Target: $17 → $15
Current: $14.49
Upside: +0.07%
Dec 17, 2025
Initiates: Buy
Price Target: $64
Current: $71.90
Upside: -10.99%
Dec 9, 2025
Maintains: Buy
Price Target: $16 → $30
Current: $6.94
Upside: +332.28%
Dec 9, 2025
Maintains: Buy
Price Target: $60 → $100
Current: $45.33
Upside: +120.60%
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $3.67
Upside: +15.80%
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $16.85
Upside: -70.33%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $2.91
Upside: +243.64%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $2.25
Upside: +77.78%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.76
Upside: +219.15%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $3.26
Upside: +360.12%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $31.54
Upside: +153.65%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.89
Upside: +419.03%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $28.62
Upside: +74.70%